Imagia secures an additional $7M of funding from Québec to further accelerate the development of its EVIDENS platform

Imagia secures an additional $7M of funding

Montréal, Canada- March 2, 2021- Imagia, a leader in artificial intelligence and personalized healthcare announced today a $7M support from Investissement Québec as part of Imagia’s  last  financing round.  This funding supports the development of the EVIDENSTM platform and the company’s expansion of its platform in Canada, the US and Europe.  Imagia’s Canadian investors include BDC Capital, Desjardins Capital and Fidelity Investments Canada ULC (certain funds), Anges Québec Capital and PME Montréal. The company has raised over $46M of financing to date.

“A world of possibilities is opening up for Québec by combining artificial intelligence with life sciences—two sectors in which Québec enjoys a competitive advantage. Through our involvement in this Imagia project, the government is supporting the development of precision medicine to improve patient care in Québec and around the world,” says Pierre Fitzgibbon, Minister of Economy and Innovation.

“AI discoveries that can accelerate diagnosis and treatment selection for better patient outcomes have been limited due to the lack of data access”, says Alexandre Le Bouthillier, Co-founder and CCO, Imagia.  ‘’This new funding will unlock the next stage of the deployment and development of Imagia EVIDENSTM allowing medical professionals who are non-AI experts to conduct their discoveries more autonomously and at an accelerated pace.’’

“As a leader in digital healthcare, we are leveraging our expertise in AI and technology to advance medical innovations through collaboration”, said Geralyn Ochab, CEO at Imagia.

Imagia’s growing ecosystem includes healthcare, AI expertise and industry partners internationally. With a patient-centric approach, Imagia activates the infrastructure for accelerated scientific discoveries, better diagnostics and more effective treatments to improve the health of patients with high-burden diseases like cancer and Alzheimer’s. EVIDENSTM is the company’s AI-platform that transforms real-world data: such as electronic health records, lab reports and images to design evidence-based clinical studies into actionable real-world evidence. Through federated learning, EVIDENSTM gains insights on decentralized patient data while preserving privacy.

About Imagia

Imagia, an artificial intelligence and healthcare company, develops digital medical innovations that aim to improve the health of cancer patients and those with other heavy-burden diseases. Through its collaborative ecosystem, Imagia EVIDENSTM enables hospitals, medical device manufacturers, pharmaceutical companies, and diagnostic companies around the world to access and utilize healthcare data while preserving data privacy. Headquartered in Montreal, Imagia’s mission is to unlock the potential of data across all organizations to achieve collaborative, medical breakthroughs.

Media Contact:

Imagia
Elpi Klapa
Marketing Director
[email protected] +1 514 652 3574

Office of the Minister of Economy and Innovation
Mathieu St-Amand
Director of Communications
418 691-5650

Related posts

A Two-Stream Continual Learning System With Variational Domain-Agnostic Feature Replay

A Two-Stream Continual Learning System With Variational Domain-Agnostic Feature Replay

Lao, Qicheng, Xiang Jiang, Mohammad Havaei, and Yoshua Bengio.IEEE Transactions on Neural Networks and Learning Systems (2021).


...
Read more
Imagia secures an additional $7M of funding  from Québec to further accelerate the development of its EVIDENS  platform

Imagia secures an additional $7M of funding from Québec to further accelerate the development of its EVIDENS platform

Imagia, a leader in artificial intelligence and personalized healthcare announced today a $7M support from Investissement Québec as part of

...
Read more
How HDMI supports groundbreaking possibilities in healthcare

How HDMI supports groundbreaking possibilities in healthcare

The process of labeling data is costly, tedious and is a very manual task  tackled by humans. Current machine learning algorithms require a

...
Read more